According to a new report Global Inflammatory Bowel Disease Treatment Market, published by KBV research, The Global Inflammatory Bowel Disease Treatment Market size is expected to reach $29.2 billion by 2027, rising at a market growth of 8.1% CAGR during the forecast period.
In 2020, the injectable segment garnered the highest market share of the inflammatory bowel disease treatment market. This is attributed to the high effectiveness of injectable drugs. Injectables comprise Entyvio (vedolizumab), IL inhibitors like Stelara (ustekinumab), TNF inhibitors like Remicade (infliximab), anti-integrin Tysabri (natalizumab), Cimzia (certolizumab), and Humira (adalimumab). Moreover, the high cost of these drugs and high prescription rate are the key factors boosting the growth of the injectables segment.
The online pharmacy segment is anticipated to showcase the fastest CAGR of the inflammatory bowel disease treatment market over the forecasting period. The factors escalating the growth of the segment are the flexibility and comfortability in online medicine purchasing and rising online consultations from expertise or doctors. Additionally, improvement in rules & regulations and increasing penetration of the internet for online purchasing of medicinal products are other factors surging the growth of the segment.
In 2020, North America emerged as the leading region in the inflammatory bowel disease treatment market by acquiring the largest revenue share and is anticipated to continue its dominance during the forecasting years. The factors bolstering the growth of the segment in this region are supportive reimbursement scenario, the growing rate of treatment, and escalating prescription of novel drugs.
Full Report: https://www.kbvresearch.com/inflammatory-bowel-disease-treatment-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Allergan PLC (AbbVie), Johnson & Johnson, Merck Group, Amgen, Inc., Eli Lilly and Company, Biogen, Inc., Pfizer, Inc., Novartis AG, Takeda Pharmaceutical Company Limited, and UCB S.A.
By Type
By Distribution Channel
By Route of Administration
By Drug Class
By Geography
Companies Profiled
Unique Offerings 
